Dr. Mike Holfinger Joins Alladapt as Chief Technical Officer MENLO PARK, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Alladapt Immunotherapeutics Inc., a private, clinical-stage biopharmaceutical company focused on the development of prescription therapeutics...

Alladapt Commences Phase 1/2 Clinical Trial in Food Allergy − Harmony Study began dosing patients who are allergic to one food or to multiple foods in a Phase 1/2 clinical trial – − ADP101 is an investigational oral immunotherapy product candidate...

Alladapt Immunotherapeutics Secures $60 Million in Series C Financing for Development of Food Allergy Therapeutics − Proceeds to support clinical advancement of ADP101, a broad-spectrum oral biopharmaceutical candidate targeting food allergy − − Financing led by Gurnet Point Capital and supported by a consortium...